Magazine Article | April 3, 2023

U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

If you have worked in the pharmaceutical industry for at least 10 years, you will remember the curious case of Amarin Corp and its highly purified prescription fish oil product, Vascepa. An omega- 3 fatty acid, the drug was first approved in 2012 for patients with high triglyceride levels to help reduce the risk of cardiovascular events. After the FDA rejected a product label expansion in 2014, saying it needed to wait for results from the 8,000-person REDUCE-IT trial, Amarin filed a lawsuit in May 2015 that argued for the company’s right to promote the drug off label, saying its promotional messages met the First Amendment standard of being “truthful and nonmisleading.” To the great surprise of many, a federal court ruled in favor of the company.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader